# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:EYEN) with a Buy and maintains $12 price target.
Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric pro...
Eyenovia (NASDAQ:EYEN) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by...